| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 10:30 | THG's Matthew Moulding increases stake to 25% following loan conversion | ||
| 10:30 | TotalEnergies to acquire 40% stake in Namibia's Mopane discovery | ||
| 10:30 | Morgan Stanley discloses trading activity in Avadel Pharmaceuticals | ||
| 10:30 | Morgan Stanley reports trading in Avadel Pharmaceuticals shares | ||
| 10:30 | Yakult Q2 2025 slides: Revenue declines amid domestic challenges, international recovery | ||
| 10:18 | Great Southern Copper reports high-grade copper findings in Chile | ||
| 10:18 | Hensoldt partners with Lockheed Martin for German naval systems | ||
| 10:18 | Nomura upgrades VS Industry stock rating to Buy on valuation | ||
| 10:06 | Boa Safra Q3 2025 slides: 56% revenue surge amid portfolio diversification | ||
| 10:06 | Google faces EU antitrust probe over AI practices | ||
| 10:06 | Ford turns to Renault to reboot European business amid Chinese competition | ||
| 10:06 | Jollibee Q3 2025 slides: International expansion drives 16.8% sales growth | ||
| 10:06 | Orbital Marine Power secures £7m for tidal energy expansion | ||
| 10:06 | Goldman Sachs upgrades Viking Holdings stock to Buy on pricing power | ||
| 10:06 | RBC Capital upgrades Colgate-Palmolive stock to Outperform on favorable setup | ||
| 09:42 | Cellebrite Q3 2025 slides: 18% revenue growth amid digital investigation expansion | ||
| 09:42 | Linamar Q3 2025 slides: Mobility growth offsets Industrial headwinds, EPS up 6.8% | ||
| 09:42 | Afya Q3 2025 slides: Double-digit growth across key metrics with margin expansion | ||
| 09:42 | KinderCare Q3 2025 slides: Portfolio expansion offsets declining margins | ||
| 09:42 | eGain Q1 2026 slides: revenue up 8%, AI Knowledge ARR grows 23% YoY | ||
| 09:42 | Berenberg downgrades Swiss Re stock to Hold on balanced risk/reward | ||
| 09:42 | Berenberg initiates Rosebank Industries stock with Buy rating, GBP4.40 target | ||
| 09:42 | RBC Capital upgrades RPM International stock on growth outlook | ||
| 09:42 | JPMorgan initiates Vor Biopharma stock with Overweight rating on telitacicept potential | ||
| 09:42 | JPMorgan initiates Vor Biopharma stock with Overweight rating, $43 target |